Biocept’s patented Target Selector(TM) test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options
SAN DIEGO, Nov. 21, 2019 /PRNewswire… […]
SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced today that it has d… […]
SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, today announced that it has co… […]
The new facility will house TriLink BioTechnologies, a Maravai LifeSciences company, and a state-of-the-art biotech manufacturing facility
SAN DIEGO, Nov. 20, 2019 /PRNewswire/ — mRNA Day is being celebrated in the City of San Diego following a proc… […]
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks
SAN DIEGO, Nov. 19, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical compan… […]
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]
– San Diego Business Journal Recognizes the City’s Top 15 Female Business Leaders –
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Busin… […]
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended S… […]
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]
– Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019- The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019-… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
